Q1/FY2023 FINANCIAL RESULTS
ENDED JUNE 30, 2023

from the beginning

Q1/FY2023 FINANCIAL RESULTS ENDED JUNE 30, 2023

CAUTIONARY STATEMENT REGARDING FORWARD LOOKING INFORMATION

Q1/FY2023 Consolidated Financial Results

• Q1/FY2023 FINANCIAL RESULTS: OVERVIEW

• Q1/FY2023 FINANCIAL RESULTS

• Q1/FY2023 FINANCIAL RESULTS: MAIN PRODUCTS

• VEOZAH: BUSINESS UPDATE

• Q1/FY2023 FINANCIAL RESULTS: COST ITEMS

• FY2023 REVISED FORECAST

Initiatives for Sustainable Growth

• XTANDI AND STRATEGIC PRODUCTS: KEY EVENTS EXPECTED IN FY2023

• ENZALUTAMIDE / XTANDI: LATEST DATA

• ENFORTUMAB VEDOTIN / PADCEV: LATEST DATA

• ACQUISITION OF IVERIC BIO

• PROGRESS IN FOCUS AREA APPROACH (1/2): CURRENT STATUS OF PROJECTS IN CLINICAL TRIAL

• PROGRESS IN FOCUS AREA APPROACH (2/2): COLLABORATIONS IN PF TARGETED PROTEIN DEGRADATION

• TOWARD ACHIEVEMENT OF CSP2021

APPENDIX

• CHANGE EXCHANGE RATES USED FOR ELIMINATION OF UNREALIZED PROFIT ON INVENTORIES (PRO FORMA FIGURES)

• Q1/FY2023: REVENUE BY REGION

• Q1/FY2023 FINANCIAL RESULTS: XTANDI (REGION)

• Q1/FY2023 FINANCIAL RESULTS: PADCEV (REGION)

• Q1/FY2023 ACTUAL:FX RATE

• FY2023 FORECAST: FX RATE & FX SENSITIVITY

• BALANCE SHEET & CASH FLOW HIGHLIGHTS

• CAPITAL ALLOCATION

• ROBUST PIPELINE OF ASTELLAS

• PROGRESS IN OVERALL PIPELINE Phase 1 Entry to Approval since the Last Financial Results Announcement

• XTANDI AND STRATEGIC PRODUCTS: STATUS UPDATE

• XTANDI AND STRATEGIC PRODUCTS:POTENTIAL PEAK SALES(AS OF JULY)

• ENZALUTAMIDE (1/2): ANDROGEN RECEPTOR INHIBITOR

• ENZALUTAMIDE (2/2): PHASE 3 STUDY DATA BY DISEASE STAGE

• ENFORTUMAB VEDOTIN (EV) (1/4): NECTIN 4 TARGETED ADC OVERALL UC PROGRAM

• ENFORTUMAB VEDOTIN (EV) (2/4): CLINICAL STUDIES

• ENFORTUMAB VEDOTIN (EV) (3/4): STUDY DATA BY DISEASE STAGE OF UC

• ENFORTUMAB VEDOTIN (EV) (4/4): FUTURE OUTLOOK

• GILTERITINIB: FLT3 INHIBITOR

• ZOLBETUXIMAB: ANTI-CLAUDIN 18.2 MONOCLONAL ANTIBODY

• FEZOLINETANT: NK3 RECEPTOR ANTAGONIST

• AVACINCAPTAD PEGOL (ACP): COMPLEMENT C5 INHIBITOR / PEGYLATED RNA APTAMER

• FOCUS AREA APPROACH: KEY EVENTS EXPECTED IN FY2023

• ON THE FOREFRONT OF HEALTHCARE CHANGE

Questions

• Questions 1

• Questions 2

• Questions 3

• Questions 4

• Questions 5

• Questions 6

• Questions 7

• Questions 8

• Questions 9